Gregory K. Palm
Director/Board Member at Olatec Therapeutics LLC
Gregory K. Palm active positions
| Companies | Position | Start | End |
|---|---|---|---|
Olatec Therapeutics LLC
 Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Director/Board Member | 2021-07-28 | - |
Career history of Gregory K. Palm
Former positions of Gregory K. Palm
| Companies | Position | Start | End |
|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | General Counsel | 1992-04-30 | - |
| Corporate Secretary | 1992-04-30 | - |
Training of Gregory K. Palm
| Harvard Business School | Graduate Degree |
| Massachusetts Institute of Technology | Undergraduate Degree |
Statistics
International
| United States | 5 |
Operational
| General Counsel | 1 |
| Corporate Secretary | 1 |
| Director/Board Member | 1 |
Sectoral
| Finance | 3 |
| Health Technology | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| THE GOLDMAN SACHS GROUP, INC. | Finance |
| Private companies | 1 |
|---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Gregory K. Palm
- Experience
